Comparing Magnesium 2g Versus 4g Versus Placebo in the Incidence of Treating AFF RVR

Launched by WAKE FOREST UNIVERSITY HEALTH SCIENCES · Apr 15, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how different doses of magnesium can help treat a heart condition called Atrial Fibrillation with Rapid Ventricular Response (AFF RVR), which causes the heart to beat too fast. The researchers want to find out if giving patients 2 grams or 4 grams of magnesium through an IV is safe and effective compared to a placebo, which is a treatment that has no active ingredients. This study is currently looking for participants aged 18 and older who can give their consent and have a primary diagnosis of AFF RVR with a heartbeat of 120 beats per minute or more.

To be eligible, participants must be able to speak English and not have certain medical conditions that could complicate their treatment, such as severe heart issues, kidney problems, or pregnancy. Those who join the trial will receive either magnesium or a placebo, and all participants will not know which treatment they are receiving to ensure fair results. This study aims to help doctors better understand how to manage this heart condition and improve patient care.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age \> 18 years or older
• • Able to provide informed consent
• • Primary diagnosis AFF RVR greater than or equal to 120 bpm
• • Diltiazem as rate control agent
• • English speaking
• Exclusion Criteria:
• • Hemodynamically unstable patients (SBP \<90, MAP \<65)
• • Impaired consciousness
• • End stage renal disease on hemodialysis or peritoneal dialysis
• • Acute heart failure exacerbation based on clinical diagnosis, physician exam, bedside echo, and/or additional imaging
• • Patient in AFF RVR that is highly suspected to be a compensatory mechanism for an alternative clinical diagnosis
• • Rhythms other than AF, such as sick sinus syndrome or wide-complex ventricular response
• • Acute myocardial infarction
• • Pregnancy defined as a positive urine HCG (human chorionic gonadotropin)
• • Contraindications to magnesium sulfate (including myasthenia gravis)
• • Allergy or sensitivity to any study drugs
• • Previously enrolled in this trial during a different patient encounter
• • Withdrew from study